TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: GlutN : Randomized, Double-blind, Crossover Clinical Trial to Confirm the Role of Gluten in Non-celiac Gluten Sensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Man or woman, aged over 18, suspected of gluten sensitivity defined by the existence of digestive and extradigestive symptoms when consuming foods containing gluten, disappearing in the absence of gluten consumption.~* Patient able to provide informed consent to participate in research.~* Patient covered by a Social Security plan.~Exclusion Criteria:~* - Weight \< 45 kg~* Celiac disease: presence of anti-tissue transglutaminase and/or anti-endomysium autoantibodies and/or villous atrophy found on duodenal biopsies.~* Wheat allergy: presence of IgE specific to wheat and/or positivity of prick tests and/or patch tests.~* Presence of another food intolerance/sensitivity, in particular to vegetables and fruits rich in FODMAPs, excluding lactose intolerance (extremely common, 30 to 50% of the French population).~* Presence only of digestive symptoms, without extradigestive symptoms, when consuming foods containing gluten.~* Impossibility of eliminating celiac disease: HLA DQ2 or DQ8 patient, for whom we do not have a dosage of anti-transglutaminase/anti-endomysium antibodies and/or duodenal histology on a normal diet containing gluten.~* Current special diet: vegetarian diet except ovo-lactovegetarian or ovo-lacto-pescovegetarian (i.e. pesco-vegetarian diet, vegan/vegan diet, macrobiotic diet, etc.), Paleolithic diet, etc.~* Pregnant or breastfeeding women.~* Treatment in progress or for less than two months with NSAIDs, corticosteroids, antibiotics, probiotics, food supplement (glutamine, omega3, antioxidants, etc.) and any other treatment likely to interfere with the study (left to the discretion of the patient). 'investigator).~* Current treatment or for less than 18 months with immunosuppressants, chemotherapy.~* History of digestive surgical intervention (except cholecystectomy and appendectomy).~* Any infectious or inflammatory pathology in progress or less than a month old and any other pathology likely to interfere with the protocol (left to the discretion of the investigator).~* Individual under guardianship, curatorship or legal protection, or deprived of freedoms.~* Participation in another clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women over the age of 40 and less than 45 years old presenting for IVF treatment.~* Willingness to sign informed consent for study randomization.~* Willingness to participate in 2 months pre-IVF treatment.~Exclusion Criteria:~* Medical condition that would contraindicate pregnancy, ovulation induction or general anesthesia.~* Family history of significant genetic disease, or factor V Leiden thrombophilia.~* Inability to present for monitoring visits.~* Inability to follow medication instruction.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Dehydroepiandrosterone (DHEA) 25mg tid
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Recovery After Dialysis-Requiring Acute Kidney Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult inpatients with AKI-D due to acute tubular necrosis who have already initiated renal replacement therapy~* If initiated on CRRT, patients will be eligible only if they have already tolerated 1 intermittent hemodialysis (IHD) session at the research site.~* If transferred from an outside hospital, eligible patients must have tolerated 1 IHD session at the research site prior to enrollment.~* Not requiring vasopressor support~* Not intubated and not having a supplemental oxygen requirement of \>5 L/min via nasal cannula~* Treating MDs (nephrology and primary team attendings) and patient (or legally authorized representative) consent to enrollment~Exclusion Criteria:~* Diagnosis of end-stage renal disease (ESRD) or chronic dialysis prior to hospitalization~* Baseline estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73m2~* Liver transplant unit patients~* Patients who underwent kidney transplantation during index hospitalization~* Cause of AKI-D is complete nephrectomy~* Current pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- TIW Dialysis Strategy (Type: ACTIVE_COMPARATOR): Conventional thrice-weekly acute intermittent hemodialysis treatment schedule.
- Conservative Dialysis Strategy (Type: EXPERIMENTAL): Conservative acute intermittent hemodialysis strategy, in which hemodialysis is not continued unless specific metabolic or clinical indications for RRT are present.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of NSCLC stage IIIA-B.~* Nonresectable or medically inoperable patients.~* No prior chemo- or radiotherapy for NSCLC.~* PS 0-1.~* FEV1 \> 1 l or \> 40% and CO diffusion capacity \> 40%.~* Patient compliance and geographic proximity that allow adequate follow-up.~* Adequate bone marrow reserve: WBCC \>3.0, platelets \>100, haemoglobin \> 100.~* Written informed concent.~* Effective use of contraception.~Exclusion Criteria:~* Excessive weight loss within 6 months (\> 10%).~* Supraclavicular nodes.~* Apical tumors-pancoast.~* T4 tumors with separate manifestations in different lobes.~* Evidence of active serious infections.~* Inadequate liver function.~* Inadequate kidney function.~* Pregnancy.~* Breast feeding.~* Serious concomitant systemic disorder.~* Second primary malignancy the last 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm A:Standard radiochemotherapy (Type: ACTIVE_COMPARATOR): Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation.
- Arm B Escalated radiochemotherapy (Type: EXPERIMENTAL): Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have given written informed consent (signed and dated) and any authorizations required by local law~2. 18 to 75 years old (inclusive)~3. Male or female with a diagnosis of PBC, by at least two of the following criteria:~   * History of AP above ULN for at least six months~  * Positive Anti-Mitochondrial Antibodies (AMA) titers (\>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies~  * Documented liver biopsy result consistent with PBC~4. On a stable and recommended dose of UDCA for the past twelve months~5. AP ≥ 1.67 × ULN~6. For females of reproductive potential, use of at least one barrier contraceptive and a second effective birth control method during the study and for at least two weeks after the last dose. For male subjects, use of appropriate contraception (e.g., condoms), so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dose~Exclusion Criteria:~1. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)~2. AST or ALT \> 3 × ULN~3. Total bilirubin \> 2 × ULN~4. Auto-immune hepatitis~5. Primary sclerosing cholangitis~6. Known history of alpha-1-Antitrypsin deficiency~7. Known history of chronic viral hepatitis~8. Creatine kinase above ULN~9. Serum creatinine above ULN~10. For females, pregnancy or breast-feeding~11. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months preceding screening~12. Current use of fibrates, including fenofibrates, or simvastatin~13. Use of an experimental treatment for PBC~14. Use of experimental or unapproved immunosuppressant~15. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Dose (Type: PLACEBO_COMPARATOR): Placebo Capsule Two Capsules Daily
- Seladelpar / MBX-8025 50 mg Dose (Type: EXPERIMENTAL): MBX-8025 50 mg capsule One Capsule Daily
- Seladelpar / MBX-8025 200 mg Dose (Type: EXPERIMENTAL): MBX-8025 100 mg capsules (2 taken once daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Uterus Transplantation by Robotics - Gothenburg III

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Uterine factor infertility, age 18-38 years, psychological stable, in steady relationship.~Exclusion Criteria:~Smoking, systemic disease, psychological instability

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Robotic surgery (Type: EXPERIMENTAL): Robotic surgery in both live donor and recipient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ulcerative colitis diagnosis by Lennard-Jones criteria~* ≥18 years~* Left or extended extent of disease~* Moderate flares of ulcerative colitis according to disease activity index (DAI)~* No maintenance therapy or 5ASA treatment~* The patient is available to understand study procedures and to sign the inform consent form~* Inform Consent Form~Exclusion Criteria:~* Previous or current thiopurines, methotrexate or biological treatment~* Administration of systemic corticoids the last 6 months~* Acute or moderate systemic infection~* Diabetes mellitus or arterial hypertension~* Pregnancy or breastfeeding~* Allergic reactions associated to corticosteroids therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- methylprednisolone & prednisone (Type: EXPERIMENTAL): Intravenous bolus of methylprednisolone followed by a decreasing conventional course of oral prednisone
- prednisone (Type: ACTIVE_COMPARATOR): A decreasing conventional course of oral prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of gynecologic malignancy~* No chemotherapy in the last 12 months~* Scheduled to receive Carboplatin (AUC\>=4) and Paclitaxel every three weeks~* ECOG performance status 0 or 1~* English speaking~* Willing and able to provide informed consent~* Laboratory values within protocol-defined parameters~* No vomiting in the 24 hours prior to initiating chemotherapy~* If childbearing potential exists, negative pregnancy test within 7 days prior to registration~Exclusion Criteria:~* Significant cognitive compromise~* History of CNS disease (e.g. brain metastases, seizure disorder, dementia)~* Current or recent (within 30 days) treatment with another antipsychotic agent (antidepressant medications are OK)~* Concurrent radiotherapy treatment~* Known hypersensitivity to olanzapine~* Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the last six months~* History of diabetes mellitus on medication (insulin or oral glycemic agent)~* Alcohol abuse / chronic alcoholism~* History of closed angle glaucoma~* Current enrollment in other clinical trials

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Nk1-RA (Type: ACTIVE_COMPARATOR): Nk1-RA will be given on day 1 of each 3-week chemotherapy cycle, for up to 6 cycles.
- Olanzapine (Type: EXPERIMENTAL): Olanzapine will be given on days 1-4 of each 3-week chemotherapy cycle, for up to 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Default BP Medication Intensification

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 55 years old~* office BP of ≥160 mmHg systolic and ≥100 mmHg diastolic (treated or untreated) AND \<180 mmHg systolic.~Exclusion Criteria:~* chronic kidney disease~* symptomatic coronary artery disease~* congestive heart failure~* more than mild valvular heart disease~* Diabetes mellitus~* obstructive left ventricular hypertrophy~* severe electrolyte abnormalities~* multiple medication intolerances~* orthostatic hypotension~* cognitive impairment and mental disorders affecting ability to self-monitor BP~* patients who are unwilling to measure and transmit BP readings throughout the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- default intensification arm (all) (Type: EXPERIMENTAL): all subjects will receive blister packs with weekly increasing blood pressure medications. There is no control arm for this study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Elders Preserving Independence in the Community

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age and income qualified tenants in 18 identified older adult low income independent living apartment buildings.~Exclusion Criteria:~* Non-tenants in 18 identified buildings~* Assessed to be cognitively impaired and unable to consent.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- In-home Preventive Health Visits by Advanced Practice Nurse (Type: ACTIVE_COMPARATOR): APRNs will perform in-home multidimensional health assessment with quarterly follow up visits to provide individualized patient education, negotiation of recommendations to maintain/improve health and wellness. All participants continue to receive care from their primary care provider and other community-based providers, although use might be modified. Throughout the intervention, participants are encouraged to take a primary role in the management of their own health. APRNs coach and guide the participant in navigating existing service providers as well as accessing and establishing new services. Having the program in-home promotes an atmosphere of shared decision-making, while allowing the nurse to observe the physical and social environment. Key to this model is identification of individual profiles of health strengths and health risks; recommendations and negotiation over priority health behavior change; and quarterly follow up.
- On-site Evidence-based Physical Activity, Health and Wellness Classes (Type: ACTIVE_COMPARATOR): Curriculum. There will be three categories of classes offered at sites randomized into this intervention. A physical activity class will be offered three times weekly, and will include elements of Tai Chi, fall prevention, and arthritis exercises. Class content/activity will be modified for all levels of ability. A class focused on mental health and functioning will be offered weekly, and include activities targeting depression prevention, memory enhancement, and engagement (e.g., life review, agile mind). There will also be offered a weekly multi-topic class with a repeating cycle of topics and instructors including medication management, computer literacy and electronic health records, etc.. Tenants will be engaged in choosing topics that reflect the group consensus on importance. Altogether, at each location there will be five scheduled class opportunities each week for tenants to choose among.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Local Radiotherapy Following Complete Resection of a Brain Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 years or older.~* Radiologically confirmed complete resection of a single brain metastasis on a contrast-enhanced MRI within 72 h after resection.~* Primary solid tumor, excluding hematologic malignancy, germ cell tumor, small cell lung cancer.~* Stable extracranial tumor (primary tumor and/or systemic metastases) during the last three months with or without treatment or progressive extracranial tumor and/or systemic metastases for which effective treatment is available.~* World Health Organization (WHO) performance score 0-2.~* Ability to provide written informed consent.~Exclusion Criteria:~* Prior treatment for brain metastases (i.e. surgery, stereotactic radiotherapy or WBRT).~* Distant brain metastases or radiological findings on MRI suspected for leptomeningeal tumor spread on the postoperative MRI.~* Concurrent use of systemic therapy during local stereotactic radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- observation (Type: NO_INTERVENTION): Watchful waiting
- local stereotactic radiotherapy (SRT) (Type: ACTIVE_COMPARATOR): local SRT in three fractions of 8 Gy to the surgical cavity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IGF-1 Therapy in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cystic fibrosis as proven by either sweat chloride or DNA analysis.~* Age \>= 18 yr.~* Tanner stage: Femake Breasts: 4-5 Male Genitalia: 4-5~Exclusion criteria:~* Hemoglobin A1C \> 8.5 %~* Diabetic retinopathy~* Obstructive sleep apnea~* Respiratory failure requiring mechanical ventilation.~* Status post pulmonary transplantation.~* Concurrent or recent (within past 6 months) receipt of human growth hormone.~* History of adverse side effects to growth hormone other than carbohydrate intolerance.~* Pregnancy or attempting pregnancy.~* Women who are breast feeding.~* Sexually active women who refuse to use or are incapable of responsibly using reliable contraception.~* Proven non compliance with medical regimens.~* Inability or refusal to take subcutaneous injections.~* Known allergy to components in the IGF-I preparation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IGF-1 (Type: EXPERIMENTAL): Recombinant human IGF-1
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues